j. res. pharm.

Journal of Research in Pharmacy

2630-6344

Marmara University

Pharmaceutical Sciences

Eczacılık Bilimleri

Evaluation of herb-drug interaction of Withania somnifera with anti-rheumatic drugs through high-throughput screening

https://orcid.org/0000-0002-2328-1234

Kanjilal

Satyajyoti

Department of Clinical Research, School of Biosciences & Biomedical Engineering, Galgotias University

https://orcid.org/0000-0002-4369-4060

Gupta

Ashok Kumar

chool of Medical and Allied Sciences, Galgotias University Patnaik

Ranjana

Department of Clinical Research, School of Biosciences & Biomedical Engineering, Galgotias University Dey

Amitabha

Bioassay Laboratory, Healthcare Division, Research and Development Centre Mohapatra

Satyabrata

Phytochemistry Laboratory, Healthcare Division, Research and Development Centre

06 28 2025

26 2 334 344 08 07 2021 02 19 2022

2010

Journal of Research in Pharmacy

Rheumatoid Arthritis is an autoimmune inflammatory joint disease. Disease-modifying anti-rheumatic drugs and Non-steroidal anti-inflammatory drugs are being used for its management and found to have better improvement when combined with a traditional medicine. Withania somnifera (Ashwagandha) is one among the medicinally important herb which is known to be beneficial in these conditions. The root of the plant is safely being used however, very less is known about the aerial part usage; and their interactions with anti-rheumatic drugs. Cytochrome P450 enzymes inhibition assay for subtypes CYP3A4 and CYP2D6 isozyme was used in concoction of hydroalcoholic and methanolic extracts of root and aerial part of the plant with the anti-arthritic drugs. All the four Withania somnifera extracts showed significantly higher (P100µg/mL) compared to positive control ketoconazole and Quinidine respectively. Combination of formulation and anti-rheumatic drugs showed significantly (P

Withania somnifera Ashwagandha Herb-drug interaction High-throughput screening CYP inhibition

[1] Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15. [CrossRef]

[2] Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM. Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agentsin the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64:625-639 [CrossRef]

[3] Gullick NJ, Scott DL. Co-morbidities in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2011;25:469-483. [CrossRef]

[4] Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther. 2011;13:S3. [CrossRef]

[5] Calgüneri M, Pay S, Calişkaner Z, Apraş S, Kiraz S, Ertenli I, Cobankara V. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol. 1999;17:699-704.

[6] Hasan SS, Ahmed SI, Bukhari NI, Loon WC. Use of complementary and alternative medicine among patients with chronic diseases at outpatient clinics. Complement Ther Clin Pract. 2009;15:152-157. [CrossRef]

[7] Ayurvedic Standard Treatment Guidelines. 1st Ed. 2017. Ministry of AYUSH Government of India, New Delhi, India. https://main.ayush.gov.in/sites/default/files/ASTG%20Book%20%282%29.pdf. (Accessed: 20 July 2020).

[8] Debnath PK, Chattopadhyay J, Mitra A, Adhikari A, Alam MS, Bandopadhyay SK, Hazra J. Adjunct therapy of Ayurvedic medicine with anti-tubercular drugs on the therapeutic management of pulmonary tuberculosis. J Ayurveda Integr Med. 2012;3:141-149. [CrossRef]

[9] Kogure T, Tatsumi T, Sato H, Oku Y, Kishi D, Ito T. Traditional herbal medicines (Kampo) for patients with rheumatoid arthritis receiving concomitant methotrexate: a preliminary study. Altern Ther Health Med. 2010;16:46-51.

[10] Chopra A, Doiphode VV. Ayurvedic medicine. Core concept, therapeutic principles, and current relevance. Med Clin North Am. 2002;86(1):75-89. [CrossRef]

[11] Kumar D, Arya V, Kaur R, Bhat ZA, Gupta V K, Kumar V. A review of immunomodulators in the Indian traditional health care system. J Microbiol Immunol Infect. 2012;45(3):165-184. [CrossRef]

[12] Chopra, A. Ayurvedic Medicine and Arthritis. Rheum Dis Clin North Am. 2000; 26:133-144. [CrossRef]

[13] Gupta A, Katiyar CK, Sastry JLN, Kanjilal S. Ayurvedic Pharmacopoeia of India: A Ready Reckoner. In: Katiyar CK, Khare CP, ed.Ayurveda at the turning point, 1st ed., Kruger Brentt, United Kingdom, 2017, pp.351-579.

[14] Sharma GK. Medicinal plants folklore and Ayurvedic system of medicine in the Indo-Tibetan outer Himalayas. J Tenn Acad Sci. 2000;75:38-41.

[15] Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177. [CrossRef]

[16] Atuah KN, Hughes D, Pirmohamed M. Clinical pharmacology: special safety considerations in drug development and pharmacovigilance. Drug Saf. 2004;27:535- 554. [CrossRef]

[17] Williamson EM. Drug Interactions Between Herbal and Prescription Medicines. Drug Saf 2003;26:1075-1092. [CrossRef]

[18] Izzo AA. Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol. 2005;19:1-16. [CrossRef]

[19] Coxeter PD, McLachlan AJ, Duke CC, Roufogalis BD. Herb-drug interactions: an evidence based approach. Curr Med Chem. 2004;11:1513-1525. [CrossRef]

[20] Tang W, Stearns RA. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab. 2001;2:185-198. [CrossRef]

[21] Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev. 2009;41:573-643. [CrossRef]

[22] Pandit S, Kanjilal S, Awasthi A, Chaudhary A, Banerjee D, Bhatt BN, Narwaria A, Singh R, Dutta K, Jaggi M, Singh AT, Sharma N, Katiyar CK. Evaluation of herb-drug interaction of a polyherbal Ayurvedic formulation through high throughput cytochrome P450 enzyme inhibition assay. J Ethnopharmacol. 2017;197:165-172. [CrossRef]

[23] Savai J, Pandita N, Chintamaneni M. Investigation of CYP1A interaction potential of Withania somnifera in rat and human liver microsomes. Int J Pharm Pharm Sci 2015;7:273-278.

[24] WHO monograph on selected medicinal plants, World Health Organization. Radix Withaniae. Available at: https://www.academia.edu/11956300/WHO_MONOGRAPH_ON_SELECTED_MEDICINAL_VOL_4. (Accessed on 25 July 2020).

[25] Khan MA, Ahmed RS, Chandra N, Arora VK, Ali A. In vivo, Extract from Withania somnifera root ameliorates arthritis via regulation of key ımmune mediators of inflammation in experimental model of arthritis. Antiinflamm Antiallergy Agents Med Chem. 2019;18(1):55-70. [CrossRef]

[26] Gupta A, Singh S. Evaluation of anti-inflammatory effect of Withania somnifera root on collagen-induced arthritis in rats. Pharm Biol 2014;52(3):308-320. [CrossRef]

[27] Kanjilal S, Gupta AK, Patnaik RS, Dey A. Anti-inflammatory activity of aerial and root extracts of Withania somnifera: A comparative experimental evidence. Int J Curr Res Rev 2021;13(7):142-148. [CrossRef]

[28] Ashwagandha. In: Mishra AB, Vaisya SR, ed. Bhavaprakasa of Sri Bhavamishra Guduchyadivarga, 8th Ed., Chaukhambha Sanskrit Bawan, Varanasi, India, 1993, pp.393-394.

[29] Anonymous. The Ayurvedic Pharmacopoeia of India. Part I. 1st ed. Vol. 1. New Delhi: Government of India, Ministry of Health and Family Welfare, Department of AYUSH 2001; pp. 19–20 [30] Nadkarni AK, Dr K M Nadkarni’s Indian Materia Medica, Popular Parakashan, Bombay, 1976.

[31] Kapoor LD, Handbook of Ayurvedic Medicinal Plants, CRC Press, London, 2001, pp. 337-338

[32] Ramakanth GS, Uday Kumar C, Kishan PV, Usharani P. A randomized, double blind placebo controlled study of efficacy and tolerability of Withaina somnifera extracts in knee joint pain. J Ayurveda Integr Med. 2016;7(3):151-157. [CrossRef]

[33] Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev. 2000;5(4):334-346.

[34] Kalra R, Kaushik N. Withania somnifera (Linn.) Dunal: a review of chemical and pharmacological diversity. Phytochem Rev. 2017;16, 953-87. [CrossRef]

[35] Kumar V, Dey A, Hadimani MB, Marcović T, Emerald M. Chemistry and pharmacology of Withania somnifera: An update. TANG. 2015;5:1-3. [CrossRef]

[36] Dar NJ, Hamid A, Ahmad M. Pharmacologic overview of Withania somnifera, the Indian Ginseng. Cell Mol Life Sci 2015;72(23):4445-60. [CrossRef]

[37] Budhiraja RD, Sudhir S. Review of biological activity of withanolides. J Sci Ind Res 1987;46:488–491.

[38] Tiwari R, Chakraborty S, Saminathan M, Dhama K, Singh SV. Ashwagandha (Withania somnifera): Role in safeguarding health, Immunomodulatory effects, combating infections and therapeutic applications: A review. J Biol Sci. 2014;14:77-94. [CrossRef]

[39] Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, Woods J. Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration. Curr Drug Metab. 2008;9:1063-1120. [CrossRef]

[40] Williamson EM. Interactions between herbal and conventional Medicines: the role of cytochrome P450 enzymes and p-glycoprotein. Pharmacologyonline. 2006;2:200-205.

[41] Savai J, Varghese A, Pandita N. Lack of the cytochrome P450 3A interaction of methanolic extract of Withania somnifera, Withaferin A, Withanolide A and Withanoside IV. J Pharm Negative Result. 2013;4:26-32. [CrossRef]

[42] Savai J, Varghese A, Pandita N, Chintamaneni M. Investigation of CYP3A4 and CYP2D6 interactions of Withania somnifera and Centella asiatica in human liver microsomes. Phytother Res. 2015;29:785-790. [CrossRef]

[43] Ojha S, Raj A, Roy A, Roy S. Extraction of total phenolics, flavonoids and tannins from paederia foetida l. leaves and their relation with antioxidant activity. Pharmacog J. 2018;10(3):541-7. [CrossRef]

[44] Li G, Simmler C, Chen L, Nikolic D, Chen SN, Pauli GF, van Breemen RB. Cytochrome P450 inhibition by three licorice species and fourteen licorice constituents. Eur J Pharm Sci. 2017;109:182-190. [CrossRef]